

Resource Summary Report

Generated by [nidm-terms](#) on Jul 28, 2026

Alzheimer's Disease Cooperative Study

RRID:SCR_008254

Type: Tool

Proper Citation

Alzheimer's Disease Cooperative Study (RRID:SCR_008254)

Resource Information

URL: <http://www.adcs.org/>

Proper Citation: Alzheimer's Disease Cooperative Study (RRID:SCR_008254)

Description: An initiative for Alzheimer's disease clinical studies that works to facilitate the discovery, development and testing of new drugs, and is a part of the Alzheimer's Disease Prevention Initiative. This resource has an emphasis on expanding the range of its patients, mainly by enhancing the recruitment of minority groups. There is a further emphasis placed on testing agents that cannot be patented, as well as developing novel compounds that had been developed by individuals, academic institutions and drug discovery units. This resource also helps in the development of Alzheimer's disease centers to carry out studies, as well as establish administrative, data, operations and medical cores in San Diego. This organization is specifically involved in studies demonstrating the lack of benefit associated, previously used treatments such as: the use of estrogen, non-steroidal anti-inflammatory drugs, B vitamins and a statin drug. The Alzheimer's Disease Cooperative Study also develops assessment instruments to be used in clinical trials. The most frequently used of these tools include: the Alzheimer's Disease Assessment Scale-Cognitive sub-scale (ADAS-cog), Activities of Daily Living (ADL), and the Clinical Global Impression of Change Scale (CGIC). There is also an associated tissue bank at UCSD that includes materials from the clinical trials including: human tissue, blood, plasma, DNA, urine and cerebrospinal fluid.

Abbreviations: ADCS

Resource Type: biomaterial supply resource, material resource, tissue bank

Keywords: drug, alzheimer's disease, cognitive assessment, behavioral assessment, blood, clinical trial, dementia, plasma, prevention, urine, cerebral spinal fluid, dna, image, data sharing, tissue, cognition, behavior

Related Condition: Alzheimer's disease

Funding: NIA

Availability: Public

Resource Name: Alzheimer's Disease Cooperative Study

Resource ID: SCR_008254

Alternate IDs: nif-0000-22434

Record Creation Time: 20220129T080246+0000

Record Last Update: 20260727T040435+0000

Ratings and Alerts

No rating or validation information has been found for Alzheimer's Disease Cooperative Study.

No alerts have been found for Alzheimer's Disease Cooperative Study.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#).

Abuknesha NR, et al. (2025) Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 34 Trials including 114,326 Individuals. medRxiv : the preprint server for health sciences.

Jimenez-Maggiora GA, et al. (2025) Artificial intelligence-enabled safety monitoring in Alzheimer's disease clinical trials. The journal of prevention of Alzheimer's disease, 12(1), 100002.

Qi H, et al. (2022) Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior. Pharmaceutical statistics, 21(5), 818.

Qi H, et al. (2022) Incorporating historical control information in ANCOVA models using the meta-analytic-predictive approach. Research synthesis methods, 13(6), 681.

Geifman N, et al. (2018) Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions. Alzheimer's research & therapy, 10(1), 4.

Gillis RME, et al. (2017) The contribution of an asthma diagnostic consultation service in obtaining an accurate asthma diagnosis for primary care patients: results of a real-life study. NPJ primary care respiratory medicine, 27(1), 35.

Geifman N, et al. (2017) Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. *Alzheimer's research & therapy*, 9(1), 10.

El Obaid Y, et al. (2016) Perceptions and Attitudes towards Medical Research in the United Arab Emirates: Results from the Abu Dhabi Cohort Study (ADCS) Focus Group Discussions. *PloS one*, 11(3), e0149609.

Wang J, et al. (2016) ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. *Journal of neurology, neurosurgery, and psychiatry*, 87(9), 993.

Huddlestone L, et al. (2016) Smoking and Looked-After Children: A Mixed-Methods Study of Policy, Practice, and Perceptions Relating to Tobacco Use in Residential Units. *International journal of environmental research and public health*, 13(6).

Yassine HN, et al. (2016) The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. *Alzheimer's research & therapy*, 8, 25.

Doody RS, et al. (2015) Peripheral and central effects of γ -secretase inhibition by semagacestat in Alzheimer's disease. *Alzheimer's research & therapy*, 7(1), 36.

Verma N, et al. (2015) New scoring methodology improves the sensitivity of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials. *Alzheimer's research & therapy*, 7(1), 64.

Gilmartin JF, et al. (2015) Depressive symptoms are associated with analgesic use in people with Alzheimer's disease: Kuopio ALSOVA study. *PloS one*, 10(2), e0117926.

Turner RS, et al. (2015) A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. *Neurology*, 85(16), 1383.

Lian T, et al. (2015) Genome-wide identification and transcriptional analysis of folate metabolism-related genes in maize kernels. *BMC plant biology*, 15, 204.

Holthoff VA, et al. (2015) Effects of physical activity training in patients with Alzheimer's dementia: results of a pilot RCT study. *PloS one*, 10(4), e0121478.

Kennedy RE, et al. (2015) Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change? *Alzheimer's & dementia (New York, N. Y.)*, 1(1), 46.

Banks SJ, et al. (2014) The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. *Dementia and geriatric cognitive disorders extra*, 4(3), 509.

Prins ND, et al. (2014) The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. *Alzheimer's research & therapy*, 6(4), 47.